The role of brain-derived neurotrophic factor (BDNF) in comorbid depression: Possible linkage with steroid hormones, cytokines, and nutrition

Frontiers in Psychiatry

Volumn 5, Issue SEP, 2014, Pages

  Numakawa, Tadahiro ^a   Richards, Misty ^b   Nakajima, Shingo ^a   Adachi, Naoki ^a   Furuta, Miyako ^c   Odaka, Haruki ^a   Kunugi, Hiroshi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BDNF; Cytokines; Depression; Estrogen; Flavonoids; Glucocorticoid; Obesity

Indexed keywords

4' DIMETHYLAMINO 7,8 DIHYDROXYFLAVONE; 7,8 DIHYDROXYFLAVONE; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; CYTOKINE; DIARYLPROPIONITRILE; ESTROGEN; FLAVONOID; FLUOXETINE; GLUCOCORTICOID; IMIPRAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PAROXETINE; PLACEBO; QUERCETIN; REBOXETINE; SERTRALINE; STEROID HORMONE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC;

ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN FUNCTION; BREAST CANCER; COMORBIDITY; DEPRESSION; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ESTROGEN THERAPY; HORMONE ACTION; HUMAN; HUNTINGTON CHOREA; HYPERGLYCEMIA; INFLAMMATION; LIPID DIET; MONOAMINERGIC SYSTEM; NEOPLASM; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; NUTRITION; OBESITY; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PUERPERAL DEPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSE; ZINC DEFICIENCY;

EID: 84907096914     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00136     Document Type: Article

References (140)

1. Numakawa T, Adachi N, Richards M, Chiba S, Kunugi H. Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience (2013) 239:157-72. doi: 10.1016/j.neuroscience.2012.09.073
2. Myers B, McKlveen JM, Herman JP. Glucocorticoid actions on synapses, circuits, and behavior: Implications for the energetics of stress. Front Neuroendocrinol (2014) 35:180-196. doi: 10.1016/j.yfrne.2013.12.003
3. Herbert J. Cortisol and depression: three questions for psychiatry. Psychol Med (2013) 43:449-69. doi: 10.1017/S0033291712000955
4. Sterner EY, Kalynchuk LE. Behavioral and neurobiological consequences of prolonged glucocorticoid exposure in rats: relevance to depression. Prog Neuropsychopharmacol Biol Psychiatry (2010) 34:777-90. doi: 10.1016/j.pnpbp.2010.03.005
5. Pawlby S, Hay DF, Sharp D, Waters CS, O'Keane V. Antenatal depression predicts depression in adolescent offspring: prospective longitudinal community-based study. J Affect Disord (2009) 113:236-43. doi: 10.1016/j.jad.2008.05.018
6. Holsen LM, Spaeth SB, Lee JH, Ogden LA, Klibanski A, Whitfield-Gabrieli S, et al. Stress response circuitry hypoactivation related to hormonal dysfunction in women with major depression. J Affect Disord (2011) 131:379-87. doi: 10.1016/j.jad.2010.11.024.
7. Schiller CE, O'Hara MW, Rubinow DR, Johnson AK. Estradiol modulates anhedonia and behavioral despair in rats and negative affect in a subgroup of women at high risk for postpartum depression. Physiol Behav (2013) 119:137-44. doi: 10.1016/j.physbeh.2013.06.009.
8. Wong JH, Brummelte S, Galea LA. Elevated corticosterone levels during the first postpartum period influence subsequent pregnancy outcomes and behaviours of the dam. J Neuroendocrinol (2011) 23:1156-65. doi: 10.1111/j.1365-2826.2011.02169.x
9. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 9:46-56.
10. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry (2010) 67:446-57. doi: 10.1016/j.biopsych.2009.09.033.
11. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord (2012) 139:230-9. doi: 10.1016/j.jad.2011.08.003.
12. Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss SJ, et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry (2012) 2: e199. doi: 10.1038/tp.2012.120
13. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry (2003) 54: 283-94.
14. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord (2004) 82: 175-90.
15. Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry (2013) 45:92-9. doi: 10.1016/j.pnpbp.2013.05.005
16. Stranahan AM, Arumugam TV, Mattson MP. Lowering corticosterone levels reinstates hippocampal brain-derived neurotropic factor and Trkb expression without influencing deficits in hypothalamic brain-derived neurotropic factor expression in leptin receptor-deficient mice. Neuroendocrinology (2011) 93:58-64. doi: 10.1159/000322808
17. Duthie G, Morrice P. Antioxidant capacity of flavonoids in hepatic microsomes is not reflected by antioxidant effects in vivo. Oxid Med Cell Longev (2012) 2012:165127. doi: 10.1155/2012/165127
18. Gonza´lez-Vallinas M, Gonza´lez-Castejo´n M, Rodri´guez-Casado A, Rami´rez de Molina A. Dietary phytochemicals in cancer prevention and therapy: a complementary approach with promising perspectives. Nutr Rev (2013) 71:585-99. doi: 10.1111/nure.12051
19. Briones TL, Woods J. Chronic binge-like alcohol consumption in adolescence causes depression-like symptoms possibly mediated by the effects of BDNF on neurogenesis. Neuroscience (2013) 254:324-34. doi: 10.1016/j.neuroscience.2013.09.031
20. Ichim G, Tauszig-Delamasure S, Mehlen P. Neurotrophins and cell death. Exp Cell Res (2012) 318:1221-8. doi: 10.1016/j.yexcr.2012.03.006
21. Fargali S, Sadahiro M, Jiang C, Frick AL, Indall T, Cogliani V, et al. Role of neurotrophins in the development and function of neural circuits that regulate energy homeostasis. J Mol Neurosci (2012) 48:654-9.
22. Chen A, Xiong LJ, Tong Y, Mao M. The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed Rep (2013) 1:167-176.
23. Chaieb L, Antal A, Ambrus GG, Paulus W. Brain-derived neurotrophic factor: its impact upon neuroplasticity and neuroplasticity inducing transcranial brain stimulation protocols. Neurogenetics (2014) 15:1-11. doi: 10.1007/s10048-014-0393-1
24. Kohli MA, Salyakina D, Pfennig A, Lucae S, Horstmann S, Menke A, et al. Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch Gen Psychiatry (2010) 67:348-359. doi: 10.1001/archgenpsychiatry.2009.201.
25. Murphy ML, Carballedo A, Fagan AJ, Morris D, Fahey C, Meaney J, et al. Neurotrophic tyrosine kinase polymorphism impacts white matter connections in patients with major depressive disorder. Biol Psychiatry (2012) 72:663-670. doi: 10.1016/j.biopsych.2012.04.015.
26. Li Z, Zhang Y, Wang Z, Chen J, Fan J, Guan Y, et al. The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice. J Psychiatr Res (2013) 47:8-14. doi: 10.1016/j.jpsychires.2012.10.003.
27. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med (2013) 19:197-209. doi: 10.1016/j.molmed.2012.12.007.
28. Barha CK, Dalton GL, Galea LA. Low doses of 17alpha-estradiol and 17beta-estradiol facilitate, whereas higher doses of estrone and 17alpha- and 17beta-estradiol impair, contextual fear conditioning in adult female rats. Neuropsychopharmacology (2010) 35:547-59. doi: 10.1038/npp.2009.161.
29. Smith CC, Vedder LC, McMahon LL. Estradiol and the relationship between dendritic spines, NR2B containing NMDA receptors, and the magnitude of long-term potentiation at hippocampal CA3-CA1 synapses. Psychoneuroendocrinology (2009) Suppl 1:S130-42. doi: 10.1016/j.psyneuen.2009.06.003
30. Babayan AH, Krama´r EA. Rapid effects of oestrogen on synaptic plasticity: interactions with actin and its signalling proteins. J Neuroendocrinol (2013) 25:1163-72. doi: 10.1111/jne.12108
31. Bredemann TM, McMahon LL. 17β Estradiol increases resilience and improves hippocampal synaptic function in helpless ovariectomized rats. Psychoneuroendocrinology (2014) 42:77-88. doi: 10.1016/j.psyneuen.2014.01.004.
32. Harte-Hargrove LC, Maclusky NJ, Scharfman HE. Brain-derived neurotrophic factor-estrogen interactions in the hippocampal mossy fiber pathway: implications for normal brain function and disease. Neuroscience (2013) 239:46-66. doi: 10.1016/j.neuroscience.2012.12.029
33. Yang LC, Zhang QG, Zhou CF, Yang F, Zhang YD, Wang RM, et al. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus. PLoS One (2010) 5:e9851. doi: 10.1371/journal.pone.0009851
34. Srivastava DP, Woolfrey KM, Evans PD. Mechanisms underlying the interactions between rapid estrogenic and BDNF control of synaptic connectivity. Neuroscience (2013) 239:17-33. doi: 10.1016/j.neuroscience.2012.12.004
35. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health (2005) 8:77-87.
36. Tarantino LM, Sullivan PF, Meltzer-Brody S. Using animal models to disentangle the role of genetic, epigenetic, and environmental influences on behavioral outcomes associated with maternal anxiety and depression. Front Psychiatry (2011) 2:44. doi: 10.3389/fpsyt.2011.00044
37. Pinsonneault JK, Sullivan D, Sadee W, Soares CN, Hampson E, Steiner M. Association study of the estrogen receptor gene ESR1 with postpartum depression--a pilot study. Arch Womens Ment Health (2013) 16:499-509. doi: 10.1007/s00737-013-0373-8
38. Mehta D, Newport DJ, Frishman G, Kraus L, Rex-Haffner M, Ritchie JC, et al. Early predictive biomarkers for postpartum depression point to a role for estrogen receptor signaling. Psychol Med (2014) 5:1-14.
39. Nikseresht S, Etebary S, Karimian M, Nabavizadeh F, Zarrindast MR, Sadeghipour HR. Acute administration of Zn, Mg, and thiamine improves postpartum depression conditions in mice. Arch Iran Med (2012) 15:306-11. doi: 012155/AIM.0012
40. Beckley EH, Scibelli AC, Finn DA. Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability. Psychoneuroendocrinology (2011) 36:824-33. doi: 10.1016/j.psyneuen.2010.11.004
41. Leuner B, Fredericks PJ, Nealer C, Albin-Brooks C. Chronic Gestational Stress Leads to Depressive-Like Behavior and Compromises Medial Prefrontal Cortex Structure and Function during the Postpartum Period. PLoS One (2014) 9:e89912. doi: 10.1371/journal.pone.0089912
42. Maniam J, Morris MJ. Long-term postpartum anxiety and depression-like behavior in mother rats subjected to maternal separation are ameliorated by palatable high fat diet. Behav Brain Res (2010) 208:72-9. doi: 10.1016/j.bbr.2009.11.005
43. von Poser Toigo E, Diehl LA, Ferreira AG, Mackedanz V, Krolow R, Benitz AN, et al. Maternal depression model: long-lasting effects on the mother following separation from pups. Neurochem Res (2012) 37:126-33. doi: 10.1007/s11064-011-0590-3
44. Kirshenbaum GS, Burgess CR, De´ry N, Fahnestock M, Peever JH, Roder JC. Attenuation of mania-like behavior in Na(+),K(+)-ATPase α3 mutant mice by prospective therapies for bipolar disorder: melatonin and exercise. Neuroscience (2014) 260:195-204. doi: 10.1016/j.neuroscience.2013.12.011
45. el-Mallakh RS, Wyatt RJ. The Na,K-ATPase hypothesis for bipolar illness. Biol Psychiatry (1995) 37:235-44.
46. Bourke CH, Capello CF, Rogers SM, Yu ML, Boss-Williams KA, Weiss JM, et al. Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. Psychopharmacology (Berl) (2013) 228:231-41. doi: 10.1007/s00213-013-3030-z
47. De Crescenzo F, Perelli F, Armando M, Vicari S. Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials. J Affect Disord (2014) 152-154:39-44. doi: 10.1016/j.jad.2013.09.019.
48. Hantsoo L, Ward-O'Brien D, Czarkowski KA, Gueorguieva R, Price LH, Epperson CN. A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology (Berl) (2014) 231:939-48. doi: 10.1007/s00213-013-3316-1.
49. Pinheiro RT, Pinheiro KA, da Cunha Coelho FM, de A´vila Quevedo L, Gazal M, da Silva RA, et al. Brain-derived neurotrophic factor levels in women with postpartum affective disorder and suicidality. Neurochem Res. (2012) 37:2229-34. doi: 10.1007/s11064-012-0851-9
50. de Azevedo Cardoso T, Mondin TC, Wiener CD, Marques MB, Fucolo Bde A´, Pinheiro RT, et al. Neurotrophic factors, clinical features and gender differences in depression. Neurochem Res (2014) 39:1571-1578. doi: 10.1007/s11064-014-1349-4.
51. Comasco E, Sylven SM, Papadopoulos FC, Oreland L, Sundstrom-Poromaa I, Skalkidou A. Postpartum depressive symptoms and the BDNF Val66Met functional polymorphism: effect of season of delivery. Arch Womens Ment Health (2011) 14:453-63. doi: 10.1007/s00737-011-0239-x
52. Elfving B, Buttenschøn HN, Foldager L, Poulsen PH, Andersen JH, Grynderup MB, et al. Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level. J Psychiatr Res (2012) 46:1118-1125. doi: 10.1016/j.jpsychires.2012.05.003.
53. Furuta M, Numakawa T, Chiba S, Ninomiya M, Kajiyama Y, Adachi N, et al. Estrogen, predominantly via estrogen receptor α, attenuates postpartum-induced anxiety- and depression-like behaviors in female rats. Endocrinology (2013) 154:3807-16. doi: 10.1210/en.2012-2136
54. Lund TD, Rovis T, Chung WC, Handa RJ. Novel actions of estrogen receptor-beta on anxiety-related behaviors. Endocrinology (2005) 146:797-807.
55. Donner N, Handa RJ. Estrogen receptor beta regulates the expression of tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei. Neuroscience (2009) 163:705-18. doi: 10.1016/j.neuroscience.2009.06.046.
56. Spencer-Segal JL, Tsuda MC, Mattei L, Waters EM, Romeo RD, Milner TA, et al. Estradiol acts via estrogen receptors alpha and beta on pathways important for synaptic plasticity in the mouse hippocampal formation. Neuroscience (2012) 202:131-46. doi: 10.1016/j.neuroscience.2011.11.035
57. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry (2004) 61:62-70.
58. Cucinelli F, Soranna L, Barini A, Perri C, Leoni F, Mancuso S, et al. Estrogen treatment and body fat distribution are involved in corticotropin and cortisol response to corticotropin-releasing hormone in postmenopausal women. Metabolism (2002) 51:137-43.
59. Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev (2008) (4):CD001690. doi: 10.1002/14651858.CD001690.pub2.
60. Rasgon NL, Dunkin J, Fairbanks L, Altshuler LL, Troung C, Elman S, et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. J Psychiatr Res (2007) 41:338-43.
61. Seillet C, Belz GT, Mielke LA. Complexity of cytokine network regulation of innate lymphoid cells in protective immunity. Cytokine (2014) S1043-4666(14)00162-8. doi: 10.1016/j.cyto.2014.06.002.
62. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry (2011) 70: 663-71. doi: 10.1016/j.biopsych.2011.04.013
63. Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res (2013) 47: 401-6. doi: 10.1016/j.jpsychires.2012.12.001
64. Dahl J, Ormstad H, Aass HC, Malt UF, Bendz LT, Sandvik L, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology (2014) 45: 77-86. doi: 10.1016/j.psyneuen.2014.03.019
65. Martinez JM, Garakani A, Yehuda R, Gorman JM. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety (2012) 29: 32-8. doi: 10.1002/da.20876
66. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry (2013) 73: 951-66. doi: 10.1016/j.biopsych.2013.01.001
67. Halaris A. Inflammation, heart disease, and depression. Curr Psychiatry Rep (2013) 15: 400. doi: 10.1007/s11920-013-0400-5
68. Suarez EC, Lewis JG, Krishnan RR, Young KH. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology (2004) 29:1119-28.
69. Bluthe´ RM, Laye´ S, Michaud B, Combe C, Dantzer R, Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci (2000) 12: 4447-56.
70. Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav (2013) 103:853-9. doi: 10.1016/j.pbb.2012.12.003
71. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacology (2012) 62: 419-26. doi: 10.1016/j.neuropharm.2011.08.018
72. O'Connor JC, Lawson MA, Andre´ C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry (2009) 14:511-22. doi: 10.1038/sj.mp.4002148.
73. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest (2012) 122:2940-54. doi: 10.1172/JCI61884.
74. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) (2012) 122: 143-59. doi: 10.1042/CS20110340
75. Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol (2014) pii: S1044-5323(14)00022-0. doi: 10.1016/j.smim.2014.02.009
76. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun (2007) 21: 9-19.
77. Pariante CM, Pearce BD, Pisell TL, Sanchez CI, Po C, Su C, et al. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology (1999) 140: 4359-66.
78. Wang X, Wu H, Miller AH. Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol Psychiatry (2004) 9: 65-75.
79. Szatma´ry Z, Garabedian MJ, Vilcek J. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. J Biol Chem (2004) 279: 43708-15.
80. Berkenbosch F, van Oers J, del Rey A, Tilders F, Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science (1987) 238: 524-6.
81. Song C, Zhang Y, Dong Y. Acute and subacute IL-1β administrations differentially modulate neuroimmune and neurotrophic systems: possible implications for neuroprotection and neurodegeneration. J Neuroinflammation (2013) 10: 59. doi: 10.1186/1742-2094-10-59.
82. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging (2008) 29:1380-93.
83. Tong L, Prieto GA, Krama´r EA, Smith ED, Cribbs DH, Lynch G, Cotman CW. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci (2012) 32: 17714-24. doi: 10.1523/JNEUROSCI.1253-12.2012
84. Brown KW, Levy AR, Rosberger Z, Edgar L. Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med (2003) 65: 636-43.
85. Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HW, et al. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol (2011) 14:247-53. doi: 10.1017/S1461145710000830.
86. Hayley S, Scharf J, Anisman H. Central administration of murine interferon-α induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments. Brain Behav Immun (2013) 31: 115-27. doi: 10.1016/j.bbi.2012.07.023
87. Anisman H, Poulter MO, Gandhi R, Merali Z, Hayley S. Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J Neuroimmunol (2007) 186: 45-53.
88. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol (2008)26: 4820-7. doi: 10.1200/JCO.2007.14.1978
89. Pyter LM, Pineros V, Galang JA, McClintock MK, Prendergast BJ. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A (2009) 106: 9069-74. doi: 10.1073/pnas.0811949106
90. Lamkin DM, Lutgendorf SK, Lubaroff D, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav Immun (2011) 25: 555-64. doi: 10.1016/j.bbi.2010.12.010
91. Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol (2013) 75:225-40. doi: 10.1146/annurev-physiol-030212-183708.
92. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry (2009) 70:1688-97. doi: 10.4088/JCP.08r04856blu.
93. Carvalho AF, Hyphantis T, Sales PM, Soeiro-de-Souza MG, Maceˆdo DS, Cha DS, et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev (2014) 40:349-55. doi: 10.1016/j.ctrv.2013.09.009.
94. Patani N, Jiang WG, Mokbel K. Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer. Cancer Cell Int (2011) 11:23. doi: 10.1186/1475-2867-11-23.
95. Huth L, Rose M, Kloubert V, Winkens W, Schlensog M, Hartmann A, et al. BDNF Is Associated with SFRP1 Expression in Luminal and Basal-Like Breast Cancer Cell Lines and Primary Breast Cancer Tissues: A Novel Role in Tumor Suppression? PLoS One (2014) 9:e102558. doi: 10.1371/journal.pone.0102558.
96. Martinac M, Pehar D, Karlovic´ D, Babic´ D, Marcinko D, Jakovljevic´ M. Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder. Acta Clin Croat (2014) 53:55-71.
97. Noble EE, Billington CJ, Kotz CM, Wang C. The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol (2011) 300:R1053-69. doi: 10.1152/ajpregu.00776.2010
98. Giles GE, Mahoney CR, Kanarek RB. Omega-3 fatty acids influence mood in healthy and depressed individuals. Nutr Rev (2013) 71:727-41. doi: 10.1111/nure.12066.
99. Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E, et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int (2013) 62:324-9. doi: 10.1016/j.neuint.2012.12.014.
100. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci (2013) 14:401-16. doi: 10.1038/nrn3505
101. Hong KW, Lim JE, Go MJ, Shin Cho Y, Ahn Y, Han BG, et al. Recapitulation of the association of the Val66Met polymorphism of BDNF gene with BMI in Koreans. Obesity (2012) 20:1871-5. doi: 10.1038/oby.2011.352
102. Marque´s-Iturria I, Garolera M, Pueyo R, Segura B, Hernan I, Garci´a-Garci´a I, et al. The interaction effect between BDNF val66met polymorphism and obesity on executive functions and frontal structure. Am J Med Genet B Neuropsychiatr Genet (2014) 165B:245-53. doi: 10.1002/ajmg.b.32229
103. Zhang Y, Chen M, Wu Z, Chen J, Yu S, Fang Y, et al. Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PLoS One (2013) 8:e72652. doi: 10.1371/journal.pone.0072652
104. Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol (2001) 15:1748-57.
105. Cordeira JW, Felsted JA, Teillon S, Daftary S, Panessiti M, Wirth J, et al. Hypothalamic dysfunction of the thrombospondin receptor α2δ-1 underlies the overeating and obesity triggered by brain-derived neurotrophic factor deficiency. J Neurosci (2014) 34:554-65. doi: 10.1523/JNEUROSCI.1572-13.2014
106. Woo J, Shin KO, Park SY, Jang KS, Kang S. Effects of exercise and diet change on cognition function and synaptic plasticity in high fat diet induced obese rats. Lipids Health Dis (2013) 12:144. doi: 10.1186/1476-511X-12-144
107. Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab (2013) 18:649-59. doi: 10.1016/j.cmet.2013.09.008
108. Wosiski-Kuhn M, Erion JR, Gomez-Sanchez EP, Gomez-Sanchez CE, Stranahan AM. Glucocorticoid receptor activation impairs hippocampal plasticity by suppressing BDNF expression in obese mice. Psychoneuroendocrinology (2014) 42:165-77. doi: 10.1016/j.psyneuen.2014.01.020
109. Valladolid-Acebes I, Merino B, Principato A, Fole A, Barbas C, Lorenzo MP, et al. High-fat diets induce changes in hippocampal glutamate metabolism and neurotransmission. Am J Physiol Endocrinol Metab (2012) 302:E396-402. doi: 10.1152/ajpendo.00343.2011
110. Francis HM, Mirzaei M, Pardey MC, Haynes PA, Cornish JL. Proteomic analysis of the dorsal and ventral hippocampus of rats maintained on a high fat and refined sugar diet. Proteomics (2013) 13:3076-91. doi: 10.1002/pmic.201300124
111. Wu A, Molteni R, Ying Z, Gomez-Pinilla F. A saturated-fat diet aggravates the outcome of traumatic brain injury on hippocampal plasticity and cognitive function by reducing brain-derived neurotrophic factor. Neuroscience (2003) 119:365-75.
112. Kaczmarczyk MM, Machaj AS, Chiu GS, Lawson MA, Gainey SJ, York JM, et al. Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice. Psychoneuroendocrinology (2013) 38:1553-64. doi: 10.1016/j.psyneuen.2013.01.004.
113. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, et al. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology (2011) 152:2634-43. doi: 10.1210/en.2011-0004.
114. Jazvinsˇc´ak Jembrek M, Vukovic´ L, Puhovic´ J, Erhardt J, Orsˇolic´ N. Neuroprotective effect of quercetin against hydrogen peroxide-induced oxidative injury in P19 neurons. J Mol Neurosci (2012) 47:286-99. doi: 10.1007/s12031-012-9737-1
115. Kim SS, Lim J, Bang Y, Gal J, Lee SU, Cho YC, et al. Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease. J Nutr Biochem (2012) 23:1314-23. doi: 10.1016/j.jnutbio.2011.07.012
116. Wang R, Tu J, Zhang Q, Zhang X, Zhu Y, Ma W, et al. Genistein attenuates ischemic oxidative damage and behavioral deficits via eNOS/Nrf2/HO-1 signaling. Hippocampus (2013) 23:634-47. doi: 10.1002/hipo.22126
117. Bhutada P, Mundhada Y, Bansod K, Ubgade A, Quazi M, Umathe S, et al. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice. Prog Neuropsychopharmacol Biol Psychiatry (2010) 34:955-60. doi: 10.1016/j.pnpbp.2010.04.025
118. Kawabata K, Kawai Y, Terao J. Suppressive effect of quercetin on acute stress-induced hypothalamic-pituitary-adrenal axis response in Wistar rats. J Nutr Biochem (2010) 21:374-80. doi: 10.1016/j.jnutbio.2009.01.008
119. Jalsrai A, Numakawa T, Ooshima Y, Adachi N, Kunugi H. Phosphatase-mediated intracellular signaling contributes to neuroprotection by flavonoids of Iris tenuifolia. Am J Chin Med (2014) 42:119-30. doi: 10.1142/S0192415X14500086
120. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A (2010) 107:2687-92. doi: 10.1073/pnas.0913572107
121. Chen J, Chua KW, Chua CC, Yu H, Pei A, Chua BH, et al. Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci Lett (2011) 499:181-5. doi: 10.1016/j.neulet.2011.05.054
122. English AW, Liu K, Nicolini JM, Mulligan AM, Ye K. Small-molecule trkB agonists promote axon regeneration in cut peripheral nerves. Proc Natl Acad Sci U S A (2013) 110:16217-22. doi: 10.1073/pnas.1303646110
123. Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet (2013) 22:2462-70. doi: 10.1093/hmg/ddt098
124. Swardfager W, Herrmann N, McIntyre RS, Mazereeuw G, Goldberger K, Cha DS, et al. Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci Biobehav Rev (2013) 37:911-29. doi: 10.1016/j.neubiorev.2013.03.018
125. Szewczyk B. Zinc homeostasis and neurodegenerative disorders. Front Aging Neurosci (2013) 5:33. doi: 10.3389/fnagi.2013.00033
126. Grønli O, Kvamme JM, Friborg O, Wynn R. Zinc deficiency is common in several psychiatric disorders. PLoS One (2013) 8:e82793. doi: 10.1371/journal.pone.0082793
127. Huang L, Tepaamorndech S. The SLC30 family of zinc transporters - a review of current understanding of their biological and pathophysiological roles. Mol Aspects Med (2013) 34:548-60. doi: 10.1016/j.mam.2012.05.008
128. Jeong J, Eide DJ. The SLC39 family of zinc transporters. Mol Aspects Med (2013) 34:612-9. doi: 10.1016/j.mam.2012.05.011
129. Sindreu C, Palmiter RD, Storm DR. Zinc transporter ZnT-3 regulates presynaptic Erk1/2 signaling and hippocampus-dependent memory. Proc Natl Acad Sci U S A (2011) 108:3366-70. doi: 10.1073/pnas.1019166108
130. Sindreu C, Baye´s A´, Altafaj X, Pe´rez-Clausell J. Zinc transporter-1 concentrates at the postsynaptic density of hippocampal synapses. Mol Brain (2014) 7:16. doi: 10.1186/1756-6606-7-16
131. Chowanadisai W, Graham DM, Keen CL, Rucker RB, Messerli MA. Neurulation and neurite extension require the zinc transporter ZIP12 (slc39a12). Proc Natl Acad Sci U S A (2013) 110:9903-8. doi: 10.1073/pnas.1222142110
132. Popovics P, Stewart AJ. GPR39: a Zn(2+)-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell Mol Life Sci (2011) 68:85-95. doi: 10.1007/s00018-010-0517-1
133. Perez-Rosello T, Anderson CT, Schopfer FJ, Zhao Y, Gilad D, Salvatore SR, et al. Synaptic Zn2+ inhibits neurotransmitter release by promoting endocannabinoid synthesis. J Neurosci (2013) 33:9259-72. doi: 10.1523/JNEUROSCI.0237-13.2013
134. Huang YZ, Pan E, Xiong ZQ, McNamara JO. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron (2008) 57:546-58. doi: 10.1016/j.neuron.2007.11.026
135. Xu H, Gao HL, Zheng W, Xin N, Chi ZH, Bai SL, Wang ZY. Lactational zinc deficiency-induced hippocampal neuronal apoptosis by a BDNF-independent TrkB signaling pathway. Hippocampus (2011) 21:495-501. doi: 10.1002/hipo.20767
136. Tassabehji NM, Corniola RS, Alshingiti A, Levenson CW. Zinc deficiency induces depression-like symptoms in adult rats. Physiol Behav. (2008) 95:365-9. doi: 10.1016/j.physbeh.2008.06.017
137. Młyniec K, Budziszewska B, Reczyn´ski W, Sowa-Kuc´ma M, Nowak G. The role of the GPR39 receptor in zinc deficient-animal model of depression. Behav Brain Res (2013) 238:30-5. doi: 10.1016/j.bbr.2012.10.020
138. Młyniec K, Doboszewska U, Szewczyk B, Sowa-Kuc´ma M, Misztak P, Piekoszewski W, et al. The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims. Neuropharmacology (2014) 79:290-7. doi: 10.1016/j.neuropharm.2013.12.001
139. Chen MD, Lin PY. Zinc-induced hyperleptinemia relates to the amelioration of sucrose-induced obesity with zinc r epletion. Obes Res (2000) 8:525-9.
140. Panchal SK, Poudyal H, Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr (2012) 142:1026-32. doi: 10.3945/jn.111.157263